startupsSightera raises €3M to advance AI-generated molecular gluesBelgian techbio Sightera Biosciences has raised €3 million in pre-seed financing to expand its AI drug discovery platform and advance a pipeline of small molecules in oncology and fibrosis. more ➔
clinical dataGSK setback deepens P2X3 cough drug doubtsGSK has stopped developing camlipixant for refractory chronic cough after mixed Phase 3 results, adding another setback to a P2X3 drug class that has repeatedly struggled to turn biological promise into … more ➔
investmentIsomorphic megadeal lifts UK biotech funding to five-year highUK biotech companies raised £2.11 billion in equity financing in the second quarter of 2026, as a record round for Isomorphic Labs pushed venture investment to its highest level in five years. more ➔
artificial intelligenceOrakl takes on four Sanofi cancer assetsFrench techbio Orakl Oncology has secured exclusive rights to four undisclosed oncology assets from Sanofi, giving the startup an opportunity to test whether its combination of patient-derived tumour … more ➔
M&AMission Therapeutics refocuses on CNS and sells $292M kidney drug to DimerixUK biotech Mission Therapeutics has sold its Phase 2-ready acute kidney injury drug MTX652 to Australia’s Dimerix in a deal worth up to $292 million (€254.7 million), freeing Mission to concentrate … more ➔
M&ALilly buys Europe-rooted AtaiBeckley for up to $3.8BEli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion (€3.3 billion), turning a psychedelic drug developer built from German and British roots into one of the sector’s largest pharmaceutical … more ➔
intellectual propertySanofi joins the mRNA vaccine patent warsSanofi has sued Pfizer and Moderna, alleging that their COVID-19 and respiratory syncytial virus (RSV) vaccines infringe patents covering the delivery of messenger RNA using lipid nanoparticles it acquired … more ➔
licensingAstraZeneca reunites with Dizal in $1.5bn lung cancer dealAstraZeneca has agreed to pay up to $1.5bn for global rights to Zegfrovy, an EGFR-targeted lung cancer drug developed by Dizal Pharmaceutical – the Chinese biotech it helped create nearly a decade … more ➔
Bayer AGBayerBayer rebuilds pharma while waiting for Monsanto reliefA stronger pipeline and new financing give Bayer room to manoeuvre — but investors are still watching one issue: the US glyphosate litigation. more ➔
Wuxi AppTecChinaWuXi AppTec bets on expansion in EuropeGlobal science, local innovation: In an interview with European Biotech Magazine, WuXi AppTec Co-CEO Steve Yang explains why Europe remains a key source of scientific innovation, why the company continues … more ➔
Bayer AG
Wuxi AppTec